Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glomerular Disease Clear all
Completed Phase 2 Interventional Results available

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

NCT03832114
View directory record Official record
Conditions
Glomerulonephritis
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Nov 15, 2026, 5:02 AM EST
Not yet recruiting No phase listed Observational

Relationship Between Insulin Dose and Complications in Type 1 Diabetes

NCT07911033
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Cardiovascular Diseases (CVD), Severe Albuminuria, Estimated Glomerular Filtration Rate (eGFR), Hypoglycemia (Diabetic), Vascular Calcification, Carotid-femoral Pulse Wave Velocity, Kidney Diseases
Interventions
Routine/prescribed exogenous insulin dose
Drug
Lead sponsor
Rachel Miller
Other
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 5:02 AM EST
Completed Phase 3 Interventional Results available

Renoprotection in Early Diabetic Nephropathy in Pima Indians

NCT00340678
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Losartan, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Nov 15, 2026, 5:02 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Zigakibart in Adults With IgA Nephropathy

NCT05852938
View directory record Official record
Conditions
IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions
BION-1301, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
28
States / cities
Birmingham, Alabama • Huntsville, Alabama • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 15, 2026, 5:02 AM EST
Completed Phase 4 Interventional Results available

The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate

NCT01163162
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Paricalcitol
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Nov 15, 2026, 5:02 AM EST
Completed No phase listed Observational

Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance

NCT01545531
View directory record Official record
Conditions
Renal Disease, Renal Insufficiency
Interventions
Iohexol
Drug
Lead sponsor
University of Washington
Other
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Nov 15, 2026, 5:02 AM EST
Terminated Phase 3 Interventional

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
View directory record Official record
Conditions
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions
Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 15, 2026, 5:02 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

The Impact of Glomerular Disorders on Bone Quality and Strength

NCT04528446
View directory record Official record
Conditions
Glomerular Disease, Bone Diseases, Metabolic, Bone Fracture
Interventions
Dual-energy X-ray absorptiometry, High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT), Blood draw and Urine collection, Questionnaires
Radiation · Other
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 55 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Nov 15, 2026, 5:02 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

NCT05777174
View directory record Official record
Conditions
Kidney Diseases, Kidney Injury, Kidney Failure
Interventions
MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Columbus, Ohio • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Nov 15, 2026, 5:02 AM EST
Recruiting Not applicable Interventional

MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure

NCT07349797
View directory record Official record
Conditions
Glomerular Filtration Rate, Heart Failure
Interventions
Lumitrace, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (tGFR), Iohexol
Device · Drug
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 15, 2026, 5:02 AM EST
Recruiting Phase 4 Interventional

Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial

NCT07225387
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Voclosporin
Drug
Lead sponsor
NephroNet, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Glendale, Arizona • Atlanta, Georgia • Lawrenceville, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Nov 15, 2026, 5:02 AM EST
Completed No phase listed Observational

Alport Syndrome Treatments and Outcomes Registry

NCT00481130
View directory record Official record
Conditions
Alport Syndrome
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
0 Years to 99 Years
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Nov 15, 2026, 5:02 AM EST
Terminated Not applicable Interventional Results available

Effect of Moderate Caloric Restriction on Glomerular Growth After Kidney Transplantation

NCT03607500
View directory record Official record
Conditions
Kidney Transplant; Complications, Glomerular Disease, Weight Gain, Kidney Transplant
Interventions
caloric intake reduction
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Nov 15, 2026, 5:02 AM EST
Completed Phase 3 Interventional Results available

A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

NCT02017171
View directory record Official record
Conditions
Diabetic Nephropathies, Coronary Artery Disease
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Aurora, Colorado • Denver, Colorado • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Nov 15, 2026, 5:02 AM EST
Active, not recruiting Phase 3 Interventional

Atrasentan in Patients With IgA Nephropathy

NCT04573478
View directory record Official record
Conditions
IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions
Atrasentan, Placebo, Zigakibart
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Alhambra, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 15, 2026, 5:02 AM EST
Terminated Phase 2 Interventional Results available

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

NCT05781750
View directory record Official record
Conditions
Lupus Nephritis
Interventions
zetomipzomib, placebo
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Lake Charles, Louisiana • East Providence, Rhode Island • Colleyville, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Nov 15, 2026, 5:02 AM EST
Completed Phase 2 Interventional Results available

Podocyte Retinoids

NCT00098020
View directory record Official record
Conditions
Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental
Interventions
Isotretinoin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
16 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Nov 15, 2026, 5:02 AM EST
Completed Not applicable Interventional

Vitamin D Supplementation in Glomerular Disease

NCT01835639
View directory record Official record
Conditions
Glomerular Disease
Interventions
Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
Dietary Supplement
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 30 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Nov 15, 2026, 5:02 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

Determination of Kidney Function

NCT00001978
View directory record Official record
Conditions
Kidney Disease, Proteinuria, Autoimmune / Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years and older
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1989 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Nov 15, 2026, 5:02 AM EST
Completed Not applicable Interventional Results available

Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease

NCT01684722
View directory record Official record
Conditions
Diabetes
Interventions
Vitamin D, Omega-3 fatty acids (fish oil), Vitamin D placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
1,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Nov 15, 2026, 5:02 AM EST
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

NCT02795676
View directory record Official record
Conditions
Fabry Disease
Interventions
PRX-102 (pegunigalsidase alfa), agalsidase beta
Biological
Lead sponsor
Protalix
Industry
Eligibility
18 Years to 60 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Nov 15, 2026, 5:02 AM EST
Recruiting Phase 3 Interventional

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

NCT04817618
View directory record Official record
Conditions
C3G
Interventions
Placebo, iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Aurora, Colorado • Miami, Florida • Lawrenceville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 5:02 AM EST
Completed Not applicable Interventional

Navigating the Challenges of Chronic Kidney Disease

NCT01792661
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Enhanced MyChart, Patient Navigator, MyChart
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Nov 15, 2026, 5:02 AM EST
Recruiting Phase 2 Interventional

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

NCT00977977
View directory record Official record
Conditions
Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease, Membranous Glomerulonephritis
Interventions
Rituximab Infusion, Oral Cyclosporine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 15, 2026, 5:02 AM EST